AGWCA
PTGX icon

Annis Gardner Whiting Capital Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-76
Closed -$8.01K – 1026
2026
Q1 		$8.01K Hold
76
– – ﹤0.01% 898
2025
Q4 		$6.64K Hold
76
– – ﹤0.01% 836
2025
Q3 		$5.05K Hold
76
– – ﹤0.01% 787
2025
Q2 		$4.2K Buy
+76
New +$3.65K ﹤0.01% 878

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's PTGX Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 76 shares — an estimated $8.01K sold.

Annis Gardner Whiting Capital Advisors first reported a position in PTGX in Q2 2025 and held it in 4 quarters. The position peaked at $8.01K in Q1 2026. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Annis Gardner Whiting Capital Advisors reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 76 Protagonist Therapeutics shares in Q2 2026, an estimated $8.01K.
  • Annis Gardner Whiting Capital Advisors first reported a position in Protagonist Therapeutics in Q2 2025 and held it in 4 quarters.
  • Annis Gardner Whiting Capital Advisors's Protagonist Therapeutics position peaked at $8.01K in Q1 2026.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.